Security key
501575104
Kymera Therapeutics, Inc. - COMMON STOCK (KYMR)
CUSIP: 501575104
Q1 2024 13F Holders as of 31 Mar 2024
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 67,207,302
- Total 13F value
- $2,701,742,064
- Share change
- +6,779,105
- Put/Call ratio
- 24%
- SEC-reported price per share
- $40.20
- Number of holders
- 161
- Value change
- +$296,832,171
- Number of buys
- 97
- Number of sells
- 58
- Shares outstanding
- 82,701,686
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2024
Institutions
161
Top holders
10
KYMR full security history
Ownership snapshot
Full 13F holder table
Kymera Therapeutics, Inc. SEC filings
Kymera Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of KYMR - Kymera Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BAKER BROS. ADVISORS LP
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
15/15
Latest evidence
31 Dec 2023
13F
Lead comparable stake: 7.3%
Showing 1-6 of 15 holder rows.
Quick read
BAKER BROS. ADVISORS LP leads the comparable SEC ownership view at 7.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BAKER BROS. ADVISORS LP's linked filing trail.
Comparable ownership
Top 5
BAKER BROS. ADVISORS LP
7.3%
Atlas Venture Life Science Adviso...
7.1%
PRICE T ROWE ASSOCIATES INC /MD/
6.5%
BVF INC/IL
6.2%
WELLINGTON MANAGEMENT GROUP LLP
5.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP |
13F
Company
|
7.3%
|
$152,656,327
5,995,928 shares
|
— | 31 Dec 2023 |
| Atlas Venture Life Science Advisors, LLC |
13F
Company
|
7.1%
|
$149,151,351
5,858,262 shares
|
— | 31 Dec 2023 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
6.5%
|
$135,848,000
5,335,712 shares
|
— | 31 Dec 2023 |
| BVF INC/IL |
13F
Company
|
6.2%
|
$131,419,453
5,161,801 shares
|
— | 31 Dec 2023 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
Company
|
5.8%
|
$122,604,107
4,815,558 shares
|
— | 31 Dec 2023 |
| VANGUARD GROUP INC |
13F
Company
|
4.8%
|
$101,777,980
3,997,564 shares
|
— | 31 Dec 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
161
Shares
67,207,302
Rows available
161
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2024 vs Q1 2024 Across Filers
Q1 2024 holders
161
Q1 2024 holders
161
Holder diff
0
| Investor | Q1 2024 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q1 2024 value | Value change | Value Chg % |
|---|